X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
KIO-301 acts as a reversible 'photoswitch', specifically designed to restore the eyes' ability to perceive and interpret light in visually impaired patients with retinitis pigmentos.
Lead Product(s): KIO-301
Therapeutic Area: Genetic Disease Product Name: KIO-301
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Accelagen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
KIO-101, also known as PP-001, is a next-generation small molecule inhibitor of Dihydroorotate Dehydrogenase. It has demonstrated picomolar potency with a validated mechanism that may offer greater safety and tolerability than DHODH inhibitors currently in the market.
Lead Product(s): KIO-101
Therapeutic Area: Ophthalmology Product Name: PP-001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2021
Details:
PP-001, an immune-modulating molecule, is an inhibitor of dihydroorotate dehydrogenase (“DHODH”) and is first-in-class for ophthalmology indications.
Lead Product(s): PP-001
Therapeutic Area: Ophthalmology Product Name: PP-001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2021
Details:
PP-001, EyeGate’s lead clinical-stage drug product, is a next-generation, non-steroidal, immuno-modulatory and small-molecule inhibitor of Dihydroorotate Dehydrogenase.
Lead Product(s): PP-001
Therapeutic Area: Ophthalmology Product Name: PP-001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $11.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 11, 2021
Details:
FDA has granted Aquestive's AQST-108 Fast Track designation, an oral sublingual film formulation that delivers systemic epinephrine in development utilizing proprietary Aquestive PharmFilm ® technologies for treatment of allergic reactions, including anaphylaxis.
Lead Product(s): Hyaluronic Acid,Antibiotic
Therapeutic Area: Infections and Infectious Diseases Product Name: MoxiGel
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
